Insider Trades
Common-stock transactions that officers, directors and 10% owners of healthcare companies report to the SEC on Form 4, from 2006 to today, newest first.
Insider filings are public records and are not a recommendation.
Results
25+ transactions, newest first
| Date | Insider | Relationship | Company | Transaction | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|
| McCulloch Kevin | See Remarks | Xeris Biopharma Holdings, Inc.XERS | SellS · Open-market or private sale | 25,000 | $10.00 | $250,000 | 1,614,208Direct | Form 4 filed 29 Sep 2026, on sec.gov (opens in a new tab)Filed 29 Sep 2026 | |
| McCulloch Kevin | See Remarks | Xeris Biopharma Holdings, Inc.XERS | SellS · Open-market or private sale | 15,000 | $8.49 | $127,350 | 1,639,208Direct | Form 4 filed 1 Sep 2026, on sec.gov (opens in a new tab)Filed 1 Sep 2026 | |
| Hecht Beth | See Remarks | Xeris Biopharma Holdings, Inc.XERS | SellS · Open-market or private sale | 16,666 | $8.49 | $141,494.34 | 1,127,796Direct | Form 4 filed 1 Sep 2026, on sec.gov (opens in a new tab)Filed 1 Sep 2026 | |
| Pieper Steven | See Remarks | Xeris Biopharma Holdings, Inc.XERS | SellS · Open-market or private sale | 5,000 | $8.50 | $42,500 | 1,356,053Direct | Form 4 filed 1 Sep 2026, on sec.gov (opens in a new tab)Filed 1 Sep 2026 | |
| Pieper Steven | See Remarks | Xeris Biopharma Holdings, Inc.XERS | SellS · Open-market or private sale | 5,000 | $8.50 | $42,500 | 1,361,053Direct | Form 4 filed 12 Aug 2026, on sec.gov (opens in a new tab)Filed 12 Aug 2026 | |
| Hecht Beth | See Remarks | Xeris Biopharma Holdings, Inc.XERS | SellS · Open-market or private sale | 16,666 | $8.01 | $133,494.66 | 1,144,462Direct | Form 4 filed 4 Aug 2026, on sec.gov (opens in a new tab)Filed 4 Aug 2026 | |
| McCulloch Kevin | See Remarks | Xeris Biopharma Holdings, Inc.XERS | SellS · Open-market or private sale | 15,000 | $8.02 | $120,300 | 1,676,126Direct | Form 4 filed 4 Aug 2026, on sec.gov (opens in a new tab)Filed 4 Aug 2026 | |
| McCulloch Kevin | See Remarks | Xeris Biopharma Holdings, Inc.XERS | OtherF · Shares withheld to pay tax or exercise price | 21,918 | $8.08 | $177,097.44 | 1,654,208Direct | Form 4 filed 21 Aug 2026, on sec.gov (opens in a new tab)Filed 21 Aug 2026 | |
| Shannon John Patrick Jr | Director, See Remarks | Xeris Biopharma Holdings, Inc.XERS | OtherF · Shares withheld to pay tax or exercise price | 36,645 | $8.08 | $296,091.60 | 2,898,933Direct | Form 4 filed 21 Aug 2026, on sec.gov (opens in a new tab)Filed 21 Aug 2026 | |
| Pieper Steven | See Remarks | Xeris Biopharma Holdings, Inc.XERS | SellS · Open-market or private sale | 27,600 | $8.52 | $235,152 | 1,366,053Direct | Form 4 filed 7 Jul 2026, on sec.gov (opens in a new tab)Filed 7 Jul 2026 | |
| Pieper Steven | See Remarks | Xeris Biopharma Holdings, Inc.XERS | SellS · Open-market or private sale | 17,400 | $8.50 | $147,900 | 1,393,653Direct | Form 4 filed 7 Jul 2026, on sec.gov (opens in a new tab)Filed 7 Jul 2026 | |
| Hecht Beth | See Remarks | Xeris Biopharma Holdings, Inc.XERS | SellS · Open-market or private sale | 16,666 | $8.03 | $133,827.98 | 1,161,128Direct | Form 4 filed 2 Jul 2026, on sec.gov (opens in a new tab)Filed 2 Jul 2026 | |
| KREHER NERISSA | Director | Xeris Biopharma Holdings, Inc.XERS | OtherA · Grant or award from the company | 33,582 | $0.00 | $0 | 33,582Direct | Form 4 filed 2 Jul 2026, on sec.gov (opens in a new tab)Filed 2 Jul 2026 | |
| McCulloch Kevin | See Remarks | Xeris Biopharma Holdings, Inc.XERS | SellS · Open-market or private sale | 90,000 | $8.03 | $722,700 | 1,691,126Direct | Form 4 filed 2 Jul 2026, on sec.gov (opens in a new tab)Filed 2 Jul 2026 | |
| JOHNSON JOHN | Director | Xeris Biopharma Holdings, Inc.XERS | OtherA · Grant or award from the company | 24,193 | $0.00 | $0 | 707,276Direct | Form 4 filed 5 Jun 2026, on sec.gov (opens in a new tab)Filed 5 Jun 2026 | |
| JOHNSON JOHN | Director | Xeris Biopharma Holdings, Inc.XERS | SellS · Open-market or private sale | 15,000 | $6.09 | $91,350 | 683,083Direct | Form 4 filed 5 Jun 2026, on sec.gov (opens in a new tab)Filed 5 Jun 2026 | |
| Kong Garheng | Director | Xeris Biopharma Holdings, Inc.XERS | OtherA · Grant or award from the company | 24,193 | $0.00 | $0 | 238,337Direct | Form 4 filed 5 Jun 2026, on sec.gov (opens in a new tab)Filed 5 Jun 2026 | |
| BORMANN-KENNEDY BARBARA-JEAN ANNE | Director | Xeris Biopharma Holdings, Inc.XERS | OtherA · Grant or award from the company | 24,193 | $0.00 | $0 | 150,693Direct | Form 4 filed 5 Jun 2026, on sec.gov (opens in a new tab)Filed 5 Jun 2026 | |
| BORMANN-KENNEDY BARBARA-JEAN ANNE | Director | Xeris Biopharma Holdings, Inc.XERS | SellS · Open-market or private sale | 16,000 | $6.09 | $97,440 | 126,500Direct | Form 4 filed 5 Jun 2026, on sec.gov (opens in a new tab)Filed 5 Jun 2026 | |
| HALKUFF DAWN | Director | Xeris Biopharma Holdings, Inc.XERS | OtherA · Grant or award from the company | 24,193 | $0.00 | $0 | 119,193Direct | Form 4 filed 5 Jun 2026, on sec.gov (opens in a new tab)Filed 5 Jun 2026 | |
| HALKUFF DAWN | Director | Xeris Biopharma Holdings, Inc.XERS | SellS · Open-market or private sale | 20,000 | $6.09 | $121,800 | 95,000Direct | Form 4 filed 5 Jun 2026, on sec.gov (opens in a new tab)Filed 5 Jun 2026 | |
| PERSKY MARLA | Director | Xeris Biopharma Holdings, Inc.XERS | OtherA · Grant or award from the company | 24,193 | $0.00 | $0 | 150,693Direct | Form 4 filed 5 Jun 2026, on sec.gov (opens in a new tab)Filed 5 Jun 2026 | |
| Brady James Aloysius | Director | Xeris Biopharma Holdings, Inc.XERS | OtherA · Grant or award from the company | 24,193 | $0.00 | $0 | 113,359Direct | Form 4 filed 5 Jun 2026, on sec.gov (opens in a new tab)Filed 5 Jun 2026 | |
| PERSKY MARLA | Director | Xeris Biopharma Holdings, Inc.XERS | SellS · Open-market or private sale | 15,500 | $5.90 | $91,450 | 126,500Direct | Form 4 filed 5 Jun 2026, on sec.gov (opens in a new tab)Filed 5 Jun 2026 | |
| Hecht Beth | See Remarks | Xeris Biopharma Holdings, Inc.XERS | SellS · Open-market or private sale | 16,667 | $6.06 | $101,002.02 | 1,176,506Direct | Form 4 filed 2 Jun 2026, on sec.gov (opens in a new tab)Filed 2 Jun 2026 |
Source: SEC EDGAR Form 4 filings and the SEC Insider Transactions Data Sets (2006 onward). Each row links to its Form 4 filing. Values are shares times the reported price. Nothing here is investment advice.